Streetbeat News

Analyst Ratings

CI

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Cigna (NYSE:CI) and maintained a $400 price target.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:22 pm

IGV

PLTR

T

Palantir Technologies Inc. (PLTR) has been included in the S&P 500, which Bank of America views as a 'watershed moment' likely to attract more institutional investors. The bank reiterated a Buy rating and raised the price target from $30 to $50, citing Palantir's strong financials, AI leadership, and strategic partnerships. The company is seen as a misunderstood giant in AI, with its Foundry platform being a key asset. Despite a slight dip in stock price, Palantir has shown strong year-to-date returns.

Portfolio Pulse from Piero Cingari

September 10, 2024 | 3:20 pm

RBRK

CIBC has maintained its 'Outperformer' rating on Rubrik (NYSE:RBRK) and increased the price target from $50 to $52.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:18 pm

F

Ford Motor shares declined after Wells Fargo maintained an Underweight rating and reduced its price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:17 pm

MELI

Deep-pocketed investors are showing significant interest in MercadoLibre (NASDAQ:MELI) options, with a mix of bullish and bearish sentiments. The options activity suggests a price window between $1800 and $2300. Analysts have mixed ratings, with an average target price of $2326.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 3:16 pm

WDC

Cantor Fitzgerald has reiterated its Overweight rating on Western Digital (NASDAQ:WDC) and maintained a price target of $80.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:13 pm

RBRK

Cantor Fitzgerald analyst Yi Fu Lee has reiterated an Overweight rating on Rubrik (NYSE:RBRK) and maintained a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:10 pm

DLTR

Dollar Tree shares fell after Goldman Sachs maintained a Buy rating but lowered its price target from $145 to $90.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:10 pm

CATX

Cantor Fitzgerald analyst Louis Chen has reiterated an Overweight rating on Perspective Therapeutics (AMEX:CATX).

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:07 pm

ZBH

Canaccord Genuity has maintained a Hold rating on Zimmer Biomet Holdings but lowered the price target from $120 to $115.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:07 pm